India Clinical Trials Market to grow at a Significant Rate During the Forecast Period

Rising prevalence of chronic conditions is expected to drive the growth of India clinical trials market during the forecast period.

According to TechSci Research report, “India Clinical Trials Market By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Treatment Studies, Observational, Expanded Access), By Indication (Autoimmune, Blood Disorders, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others), By End User (Hospital, Laboratories, Clinics), By Company, By Region, Forecast & Opportunities, FY2026”, the India clinical trials market is expected to grow at a steady rate during the forecast period. Increasing demand for clinical trials in the country is projected to act as major market driving factor. Moreover, growing number of biologics coupled with increasing need for personalized medicines are further expected to fuel the market growth through FY2026. Furthermore, huge and diverse population of India with chronic diseases is estimated to boost India clinical trials market growth because of which different types of trials can be conducted in one region. Thereby, helping in faster recruitment of the patients and companies to conduct the trials on the timely basis.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “ India Clinical Trials Market”

https://www.techsciresearch.com/report/india-clinical-trials-market/7239.html

The India clinical trials market is segmented based on phase, study design, indication, place of conduct, company, and region. Based on indication, the market can be fragmented into Autoimmune, Blood Disorders, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others. Out of which, the oncology segment is projected to account for largest share in the market which can be accredited to the high spending towards preclinical and clinical development of oncology therapy products by the pharmaceutical industry. The cardiovascular condition segment is projected to register fastest growth over the forecast period on account of surging incidence of cardiovascular diseases and increased demand for cost-effective medication in the country. In terms of study design, the market is categorized into Interventional, Treatment Studies, Observational, Expanded Access. The interventional design segment dominated the market with largest revenue share until FY2020 as it is one of the most prominent methods which is used in clinical trials. Besides, expanded access trials segment is estimated to witness the fastest growing CAGR during the forecast period owing to rising innovation in clinical trial methods. In addition to this, it is a potential pathway for the patients dealing with serious disease conditions so that it is possible to carry out treatment outside the trial when no satisfactory therapies are available.

Pfizer India Ltd., Ѕun Рhаrmасеutісаl Іnduѕtrіеѕ Ltd., GlaxoSmithKline Pharmaceuticals Ltd., IQVIA India Pvt. Ltd., Covance Ltd., Ноffmаnn-Lа Rосhе India Ltd., Novartis India Ltd., AstraZeneca India Pvt. Limited, Pharmaceutical Product Development Ltd., Eli Lilly and Company (India) Pvt. Ltd and others are some of the leading players operating in India clinical trials market. Companies operating in the market are using organic strategies such as collaborations with hospitals in order to conduct their clinical trials.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7239

Customers can also request for 10% free customization on this report.

“India clinical trials market is expected to witness steady growth during the forecast period on account of surging requirement for new medicines as well as medical equipment amongst the healthcare providers. Along with this, growing investments in drug development activities by major market players operating in the market is further forecasted to bode well for the growth of clinical trials market in the country. Moreover, continuous initiatives by the government of the country for the promotion of drug discovery is further expected to create lucrative opportunities for the market growth of India clinical trials market over the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.

“India Clinical Trials Market By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Treatment Studies, Observational, Expanded Access), By Indication (Autoimmune, Blood Disorders, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others), By Place of Conduct (Hospital, Laboratories, Clinics, Others), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India clinical trials market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India clinical trials market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]